The increasing use of carbapenems for treating multidrug-resistant (MDR) Gram-negative bacterial infections has contributed to the global dissemination of carbapenem-resistant Enterobacteriaceae (CRE). Serine and metallo--lactamases (MBLs) that hydrolyze carbapenems have become prevalent and endemic in some countries, necessitating the use of older classes of agents, such as colistin. A total of 19,719 isolates of Enterobacteriaceae (excluding Proteeae and Serratia spp., which have innate resistance to colistin) were collected from infected patients during 2012 and 2013 in a global surveillance program and tested for antimicrobial susceptibility using CLSI methods. Isolates of CRE were characterized for carbapenemases and extended-spectrum -lactamases (ESBLs) by PCR and sequencing. Using EUCAST breakpoints, the rate of colistin susceptibility was 98.4% overall, but it was reduced to 88.0% among 482 carbapenemase-positive isolates. Colistin susceptibility was higher among MBL-positive isolates (92.6%) than those positive for a KPC (87.9%) or OXA-48 (84.2%). Of the agents tested, only tigecycline (MIC 90 , 2 to 4 g/ml) and aztreonam-avibactam (MIC 90 , 0.5 to 1 g/ml) consistently tested with low MIC values against colistin-resistant, ESBL-positive, and carbapenemase-positive isolates. Among the 309 (1.6%) colistin-resistant isolates from 10 species collected in 38 countries, 58 carried a carbapenemase that included KPCs (38 isolates), MBLs (6 isolates), and OXA-48 (12 isolates). These isolates were distributed globally (16 countries), and 95% were Klebsiella pneumoniae. Thirty-nine (67.2%) isolates carried additional ESBL variants of CTX-M, SHV, and VEB. This sample of Enterobacteriaceae demonstrated a low prevalence of colistin resistance overall. However, the wide geographic dispersion of colistin resistance within diverse genus and species groups and the higher incidence observed among carbapenemase-producing MDR pathogens are concerning.
Multidrug resistance (MDR) in Gram-negative bacilli has limited the options for treating serious infections and is responsible for increased morbidity and mortality rates worldwide (1). Over the last decade, carbapenem-resistant Enterobacteriaceae (CRE) have spread globally and now affect patient care in nearly all geographic regions (2). Resistance to carbapenems can be caused by several mechanisms; however, the resistance can most often be attributed to the carbapenemases, which include serine enzymes, such as the KPC and OXA-type enzymes, and the metallo--lactamases (MBLs), including IMP-, NDM-, and VIM-type enzymes. Because standard therapies usually include a -lactam for treating Gram-negative bacterial infections, the limitations of treatment choices imposed by CRE require that alternative therapeutic approaches be considered, including polymyxins, fosfomycin, some aminoglycosides, and tigecycline, which are not affected by mechanisms of carbapenem resistance (3-5). These antimicrobial agents, including colistin, are now being used as last-in-line treatment options f...